

41

AF/1660
\$

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/939,872
	Filing Date	08/27/2001
	First Named Inventor	Jean Ackermann
	Art Unit	1614
	Examiner Name	C. Aulakh
Total Number of Pages in This Submission	Attorney Docket Number	20757 US


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Peter Tu
Signature	<i>Peter Tu</i>
Date	03/15/2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Peter Tu		
Signature	<i>Peter Tu</i>	Date	03/15/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



In re Patent Application

Ackermann et al

Serial No.: 09 /939,872

Filed: August 27, 2001

For: 2,3-Oxidosqualene-Lanosterol Cyclase Inhibitors

Hoffmann-La Roche Inc.

340 Kingsland Street


Nutley, NJ 07110

March 15, 2004

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450



Sir:

Transmitted herewith is an amendment in the above-identified application.

_____ page(s) of substitute Sequence Listing.

_____ computer disk(s) containing substitute Sequence Listing.

_____ Statement under 37 CFR §1.825(b) that the computer disk and paper copies of the substitute Sequence Listing are the same.

_____ Statement under 37 CFR §1.825(a) that the substituted Sheets of the Sequence Listing are supported in the application.

_____ No additional fee is required.

 X Petition for an extension of time under 37 CFR §1.136.

(Col. 1)		(Col. 2)	(Col. 3)		
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE
TOTAL 90	MINUS	75	15	x \$18	\$270
INDEP. 29	MINUS	13	16	x \$86	\$1376
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+ 290	
TOTAL					\$1646

Serial No. 09/939,872
Filed: August 27, 2001

 X Please charge my Deposit Account No. 08-2525 in the amount of \$ 1646. This sheet is provided in duplicate.

 A check in the amount of \$ is attached.

 X The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525. This sheet is provided in duplicate.



Attorney of Record

Peter Tu

(Reg. No. 43,207)

Telephone: (973) 235-2884

Telefax: (973) 235-2363

140248